[go: up one dir, main page]

MX347890B - Neuroproteccion y reparacion de melina usando progestina. - Google Patents

Neuroproteccion y reparacion de melina usando progestina.

Info

Publication number
MX347890B
MX347890B MX2012004542A MX2012004542A MX347890B MX 347890 B MX347890 B MX 347890B MX 2012004542 A MX2012004542 A MX 2012004542A MX 2012004542 A MX2012004542 A MX 2012004542A MX 347890 B MX347890 B MX 347890B
Authority
MX
Mexico
Prior art keywords
neurodegeneration
compound
myelin repair
treating
nestorone
Prior art date
Application number
MX2012004542A
Other languages
English (en)
Other versions
MX2012004542A (es
Inventor
Regine Sitruk-Ware
Michael Maria Helmut Schumacher
Martine El-Etr
Abdelmouman Ghoumari
Rachida Guennoun
Roberta Brinton
Original Assignee
The Population Council Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Population Council Inc filed Critical The Population Council Inc
Publication of MX2012004542A publication Critical patent/MX2012004542A/es
Publication of MX347890B publication Critical patent/MX347890B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una dosis farmacéuticamente efectiva de 5mg/día o inferior de 16-metileno-17 a-acetoxi-19-norpregn-4-eno-30,20-diona para usarse para la regeneración de mielina en un recipiente, en donde dicha dosis farmacéuticamente eficaz de un compuesto de progestina ejerce la unión a receptores de progesterona sin la interacción con el receptor de andrógeno y sin inducir respuestas biológicas de andrógeno o glucocorticoide.
MX2012004542A 2009-10-19 2010-10-19 Neuroproteccion y reparacion de melina usando progestina. MX347890B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27932009P 2009-10-19 2009-10-19
PCT/US2010/053201 WO2011049948A2 (en) 2009-10-19 2010-10-19 Neuroprotection and myelin repair using nestorone®

Publications (2)

Publication Number Publication Date
MX2012004542A MX2012004542A (es) 2012-11-29
MX347890B true MX347890B (es) 2017-05-18

Family

ID=43413545

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012004542A MX347890B (es) 2009-10-19 2010-10-19 Neuroproteccion y reparacion de melina usando progestina.

Country Status (9)

Country Link
US (1) US10052335B2 (es)
EP (1) EP2490680B1 (es)
JP (1) JP5871807B2 (es)
AU (1) AU2010308308B2 (es)
BR (1) BR112012009306A2 (es)
CA (1) CA2777551C (es)
ES (1) ES2669694T3 (es)
MX (1) MX347890B (es)
WO (1) WO2011049948A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9446051B2 (en) 2009-10-19 2016-09-20 The Population Council, Inc. Neuroprotection and myelin repair using nestorone®
EP2490680B1 (en) 2009-10-19 2018-04-04 The Population Council, Inc. Neuroprotection and myelin repair using nestorone®
JP6082249B2 (ja) * 2009-12-17 2017-02-15 ザ・ポピュレイション・カウンシル，インコーポレイテッド 経皮ゲル製剤
US8580294B2 (en) 2010-10-19 2013-11-12 International Partnership For Microbicides Platinum-catalyzed intravaginal rings
WO2012129365A1 (en) 2011-03-22 2012-09-27 The Population Council, Inc. Myelin regeneration with androgens
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
HRP20211377T1 (hr) 2011-11-23 2022-01-07 Therapeuticsmd, Inc. Prirodne kombinirane hormonske supstitucijske formulacije i terapije
CN102688247A (zh) * 2012-04-15 2012-09-26 温州医学院 Nestorone在制备治疗帕金森氏病的药物用途
CN102657661A (zh) * 2012-04-15 2012-09-12 温州医学院 Nestorone在制备治疗阿尔茨海默病的药物用途
US9808470B2 (en) * 2012-04-19 2017-11-07 Universite De Liege Estrogenic components for use in the treatment of neurological disorders
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CA2836388A1 (en) * 2012-12-21 2014-06-21 The Population Council, Inc. Neuroprotection and myelin repair using st-1435
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
WO2015088625A2 (en) * 2013-09-25 2015-06-18 Case Western Reserve University Compounds and methods of promoting myelination
US10137031B2 (en) 2013-11-14 2018-11-27 International Partnership For Microbicides, Inc. Combination therapy intravaginal rings
KR20170005819A (ko) 2014-05-22 2017-01-16 쎄러퓨틱스엠디, 인코퍼레이티드 천연 복합 호르몬 대체 제형 및 요법
US20160008376A1 (en) * 2014-07-10 2016-01-14 Biocopea Limited Compositions, Methods and Uses for Treating Gender-Biased Immune Disorders
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4760092A (en) * 1985-10-29 1988-07-26 The Rockefeller University Treatment of demyelinating diseases
DE60128451T2 (de) 2000-03-15 2007-08-30 OrbusNeich Medical, Inc., Fort Lauderdale Beschichtung welche ein anhaften von endothelzellen stimuliert
US6891081B1 (en) 2000-08-14 2005-05-10 The Trustees Of Columbia University In The City Of New York Transgenic mice over-expressing amyloid-beta alcohol dehydrogenase (ABAD) in brain as model of alzheimer's disease and uses thereof
US8658627B2 (en) * 2001-04-25 2014-02-25 The Regents Of The University Of California Pregnancy hormone combination for treatment of autoimmune diseases
WO2003041718A1 (en) 2001-11-15 2003-05-22 Pantarhei Bioscience B.V. Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
WO2003045362A2 (en) * 2001-11-30 2003-06-05 Solvay Pharmaceuticals Gmbh Treatment of th1 dominated immunological disease states with non-endogenous gestagen compounds
TW200400040A (en) * 2002-05-17 2004-01-01 Wyeth Corp Hormone replacement therapy
US20040087563A1 (en) 2002-11-05 2004-05-06 Siegfried Mayerhofer Hormone replacement therapy with cardiovascular protection using antialdosteronic progestins
AU2006220918A1 (en) * 2005-03-04 2006-09-14 Alsgen, Inc Treatment of amyotrophic lateral sclerosis with norethindrone and anal0gues6
EP2490680B1 (en) 2009-10-19 2018-04-04 The Population Council, Inc. Neuroprotection and myelin repair using nestorone®
CN102657661A (zh) 2012-04-15 2012-09-12 温州医学院 Nestorone在制备治疗阿尔茨海默病的药物用途
CN102688247A (zh) 2012-04-15 2012-09-26 温州医学院 Nestorone在制备治疗帕金森氏病的药物用途

Also Published As

Publication number Publication date
US20120231052A1 (en) 2012-09-13
CA2777551C (en) 2015-12-22
US10052335B2 (en) 2018-08-21
AU2010308308B2 (en) 2013-11-28
AU2010308308A1 (en) 2012-06-07
MX2012004542A (es) 2012-11-29
WO2011049948A4 (en) 2011-08-04
BR112012009306A2 (pt) 2016-06-07
ES2669694T3 (es) 2018-05-28
CA2777551A1 (en) 2011-04-28
EP2490680A2 (en) 2012-08-29
EP2490680B1 (en) 2018-04-04
JP2013508379A (ja) 2013-03-07
JP5871807B2 (ja) 2016-03-01
WO2011049948A2 (en) 2011-04-28
WO2011049948A3 (en) 2011-06-16

Similar Documents

Publication Publication Date Title
MX347890B (es) Neuroproteccion y reparacion de melina usando progestina.
WO2010088409A3 (en) Methods of neuroprotection using neuroprotective steroids and a vitamin d
MX363536B (es) Gel transdermico de progestina/estradiol.
MX2020013533A (es) Formulaciones y terapias de reemplazo de combinacion de hormonas naturales.
CY1118236T1 (el) Μεθοδος για αντισυλληψη κατ' απαιτηση
PL2097437T3 (pl) Zastosowanie steroidów pregnanowych i androstanowych do wytwarzania kompozycji farmaceutycznej do leczenia zaburzeń OUN
GB201104241D0 (en) Dosages for menstrual suppression, contraception, and hormone replacement therapy, and methods of administrating same
WO2007144152A3 (en) Extended step-down estrogen regimen
NZ609420A (en) Fulvestrant compositions and methods of use
PT2061561E (pt) Composições para tratar o cancro
MX338290B (es) Tratamiento de enfermedad de alzheimer, perdida de cognición, perdida de memoria y demencia con precursores de esteroides sexuales en conbinación con moduladores selectivos del receptor de estrógenos.
WO2009148620A3 (en) Anthraquinones and analogs from rhuem palmatum for treatment of estrogen receptor beta-mediated conditions
WO2011059969A3 (en) Mammalian metabolites of steroids
IL207182A (en) Use of 17 alpha-acetoxy-11 beta- (4– n, n– dimethylamino phenyl) –19 – norfergana – 4, 9 – dian – 3, 20 – deion (Olipristal acetate) for the preparation of a drug to lower or stop bleeding in patients suffering from uterine fibroids
AU2009256009A8 (en) Methods for preparing 17-alkynyl-7-hydroxy steroids and related compounds
MX2010005119A (es) Corticosteroides para tratar la diarrea inducida por la epotilona o los derivados de epotilona.
IL204629A0 (en) Use of glycerol, method of crop treatment, composition for tank mixing and a method of preparation of a composition for tank mixing
TW200726473A (en) Compositions and methods for treatment of cycle-related symptoms
PH12014500596A1 (en) Plant steroids and uses thereof
SI1989217T1 (sl) 11-fosforni steroidni derivati, uporabni kot modulatorji progesteronskega receptorja
PL2564900T3 (pl) Steroidy C-19 do zastosowań terapeutycznych
SI2120976T1 (sl) Metoda za zdravljenje analne inkontinence z uporabo mioblastov
WO2009059806A3 (en) Preparation of 6-oxa-8alpha-steroid estrogen analogues - a new group of unnatural estrogens and their use in medicine
IL202205A (en) Process for the preparation of steroids converted at position 17α by 3-hydroxypropyl and at position 17ß - by hydroxy from the corresponding 14-oxo history and intermediates obtained in this process
TW200730180A (en) Therapeutic uses of steroidal compounds

Legal Events

Date Code Title Description
FG Grant or registration